Jazz Pharmaceuticals v. Teva: Cannabidiol Patent Dispute Settles After 765 Days

A sweeping pharmaceutical patent infringement action involving over a dozen generic drug manufacturers has concluded with a negotiated settlement, closing one of the more complex multi-defendant cannabidiol (CBD) patent cases in recent memory. Filed on January 3, 2023, in the U.S. District Court for the District of New Jersey, Jazz Pharmaceuticals Research UK Limited v. Teva Pharmaceutical Industries, Ltd. (Case No. 2:23-cv-00018) spanned 765 days before reaching resolution on February 6, 2025.

At its core, this cannabidiol patent infringement case involved Jazz’s assertion of 26 U.S. patents covering CBD formulations, methods of treating epilepsy, tuberous sclerosis complex (TSC), and cardiovascular risk reduction — all directly tied to Jazz’s blockbuster drug Epidiolex®. With defendants ranging from Teva and Lupin to Cipla, Apotex, and MSN Pharmaceuticals, this litigation represents a defining moment in the generics-versus-innovator battle over cannabidiol therapeutics. The outcome carries significant implications for pharmaceutical patent strategy, ANDA litigation trends, and the future of the CBD drug patent landscape.

Case Overview

The Parties

The Patents at Issue

This landmark case involved three design patents covering fundamental smartphone design elements that shaped the modern smartphone industry:Jazz asserted 26 U.S. patents, spanning a broad portfolio tied to cannabidiol pharmaceutical development. Key patent numbers include:

• • US10918608B2 — Cannabidiol preparations and formulations
• • US10137095B2 — Cannabidiol preparations and formulations
• • US10709673B2 — Methods of treating tuberous sclerosis complex (TSC) with CBD and everolimus
• • US10966939B2 — Use of cannabinoids in epilepsy treatment
• • US11207292B2 — Use of cannabinoids in epilepsy treatment
• • US9956185B2 — Reducing the risk of cardiovascular adverse events
• • US11311498B2 — Cannabidiol preparations and formulations
• • US11446258B2 — Cannabidiol preparations and formulations

This multi-patent assertion strategy — stacking formulation, method-of-use, and combination therapy patents — is a hallmark of modern branded pharmaceutical lifecycle management.

The Verdict & Legal Analysis

Outcome

The case resolved via **negotiated settlement** (stipulated dismissal) — the most common outcome in Hatch-Waxman ANDA litigation. The settlement between Jazz and the final defendant, Apotex, Inc., was memorialized in a Stipulation and Order of Dismissal submitted to the Court. As Apotex was identified as the last remaining defendant, the case was fully terminated upon the Clerk’s entry of the dismissal order on February 6, 2025.

No damages award, royalty figure, or injunctive relief terms have been publicly disclosed, which is standard in pharmaceutical patent settlements where licensing terms (including authorized generic launch dates) are typically kept confidential.

Key Legal Issues

This litigation arose as a classic **Hatch-Waxman ANDA infringement action** — triggered when generic manufacturers filed Abbreviated New Drug Applications with Paragraph IV certifications asserting that Jazz’s patents were invalid, unenforceable, or would not be infringed by their proposed generic cannabidiol products.

Jazz’s multi-layered patent strategy — asserting 26 patents spanning formulation, method-of-use, and combination therapy claims — created formidable litigation economics for each defendant. Defendants faced the burden of either designing around a broad, deeply layered patent estate or litigating validity challenges across dozens of patent claims simultaneously. This “patent thicket” approach is a well-documented lifecycle management tool for branded pharmaceuticals, and it appears to have served Jazz effectively here.